Aktiesnakken — Juni 2013
-
Nordea´s eftermiddagskommentar "De danske biotekselskaber har en hård dag. Bavarian Nordic falder 5% uden
nyheder, og det går endnu hårdere ud over Genmab, som falder ca. 12%. Sidstnævnte
er presset af skriverier om, at et konkurrerende produkt til Genmabs Arzerra
udgør en stor trussel. For risikovillige investorer ser vi tilbagefaldene som
en attraktive købsmuligheder. Nordea Markets har anbefalingen Stærkt Køb på
både Genmab og Bavarian Nordic." -
300 vs. 500?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind